Local activists, business owners react to marijuana reclassification

The President signed an executive order directing the DEA to reclassify marijuana from Schedule I to Schedule III, a move that does not legalize cannabis federally but would allow recognized medical use, expand federal research and reduce certain criminal penalties. For the cannabis industry this could be material: Schedule III status would permit standard tax deductions (industry participants currently cite effective tax rates as high as 70%), enable physicians to recommend medical marijuana and improve profitability and normalization for dispensaries and related businesses. Investors should monitor DEA rulemaking, state-level regulatory responses and potential changes to banking/tax treatment that would affect margins and valuations of cannabis operators.

Analysis

Market structure: Immediate winners are U.S. multi-state operators (MSOs) and cannabis-focused REITs and service providers that will directly benefit if federal rescheduling removes Section 280E-like tax headwinds — expect median MSO EBITDA margin expansion of ~800–1,500 bps over 12–24 months as after‑tax cashflow converts loss-making operators into low‑double‑digit FCF generators. Losers include illicit small sellers (market share loss) and many Canadian LPs (CGC, ACB) that lack direct U.S. retail footprints; pricing power will concentrate with top 5 MSOs (CURLF, GTBIF, CRLBF, TCNNF). Cross-asset: expect credit spreads on cannabis corporate debt to compress 200–400 bps within 6–18 months, equity volatility to spike near headlines then settle, and negligible FX/commodity impact outside higher beta small-cap moves.

Risk assessment: Tail risks are concentrated regulatory and litigation delays — DEA/IRS rulemaking and judicial challenges could push meaningful change 6–24 months out and reintroduce retroactive tax uncertainty; banking access and state-level tax hikes are second‑order risks. Time buckets: days — headline-driven IV spikes; weeks–months — regulatory filings, IRS guidance, bank memos; quarters–years — fundamental re-rating and M&A. Hidden dependencies include banking access, state implementation differences, and potential pharma entry compressing margins. Key catalysts: DOJ/DEA notices, IRS guidance, Federal Reserve/BSA banking clarifications, and Q2–Q4 2025 earnings commentary.

Trade implications: Tactical overweight long positions in EBITDA‑capable MSOs (Curaleaf CURLF, Green Thumb GTBIF, Cresco CRLBF, Trulieve TCNNF) sized 1–3% each, opened within 2–8 weeks to capture post‑rule consolidation; target +40–100% in 12–24 months, stop-loss -30%. Pair trade: long US MSO ETF/portfolio vs short Canadian LPs (Canopy CGC, Aurora ACB) sized 1% net to exploit faster U.S. re‑rating. Options: buy 9–15 month LEAPS calls (ATM) on CURLF and GTBIF and hedge with 3–6 month put spreads (cost <50% of call premium) to limit downside while capturing upside on regulatory progress.

Contrarian angles: Consensus underestimates execution frictions — markets may be slow to price full 280E relief because IRS guidance and bank behavior could lag by 6–12 months, creating a priced-in patience premium and a buying window. Conversely, the market could also overvalue headline moves if states raise excise taxes to capture new revenue, capping upside; watch bank memos and IRS private-letter rulings as leading indicators. Historical parallel: partial deregulation-themed rallies (e.g., US vaping/TPD shifts) showed 6–12 month dispersion; prepare for a choppy multi-quarter re-rating rather than a one-day windfall.

Key Decisions for Investors

• Establish 1–3% long positions each in Curaleaf (CURLF), Green Thumb (GTBIF), Cresco Labs (CRLBF) and Trulieve (TCNNF) within 2–8 weeks; target +40–100% over 12–24 months and implement hard stop-losses at -30% to limit regulatory/timing risk.
• Implement a relative-value pair: long a US MSO basket (equal-weight CURLF/GTBIF/CRLBF) vs short Canadian LPs (Canopy CGC, Aurora ACB) sized 1% net exposure to capture faster U.S. re-rating; rebalance monthly and close if spread narrows by >25% or after 12 months.
• Buy 9–15 month ATM LEAPS calls on CURLF and GTBIF (allocate 0.5–1% of portfolio each) and sell 3–6 month put spreads up to 50% of premium paid as a hedge; exit calls on 40% gain or roll if DEA/IRS milestones are delayed beyond 12 months.
• Reduce exposure to high-yield corporate bonds of small cannabis issuers by 50% and rotate proceeds into investment-grade muni or short-dated Treasuries until clear banking guidance appears; re-enter credit if spreads compress >200 bps from current levels or after IRS guidance publication.